Halozyme Therapeutics, Inc. $HALO Stock: NorthCrest Asset Manangement LLC Increases Position

Key Points

• NorthCrest Asset Management increased its Halozyme position by 27.7% in the third quarter, bringing its holdings to 57,661 shares worth approximately $6.3 million. Institutional investors collectively own 97.79% of the company.
• Halozyme reported strong quarterly results, with EPS of $2.28 beating estimates of $1.79 and revenue rising 47.7% year over year to $481 million. The company set fiscal 2026 EPS guidance at $8.65–$9.00.
• Analyst sentiment remains generally positive, with nine Buy ratings, two Holds and one Sell; the consensus rating is “Moderate Buy.” However, company insiders sold 125,852 shares worth about $13.5 million during the last quarter.

NorthCrest Asset Manangement LLC increased its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 27.7% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 57,661 shares of the biopharmaceutical company's stock after buying an additional 12,511 shares during the period. NorthCrest Asset Manangement LLC owned about 0.05% of Halozyme Therapeutics worth $6,333,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. GK Wealth Management LLC acquired a new position in shares of Halozyme Therapeutics in the third quarter worth about $178,000. Balefire LLC boosted its holdings in Halozyme Therapeutics by 9.9% in the third quarter. Balefire LLC now owns 3,227 shares of the biopharmaceutical company's stock valued at $356,000 after purchasing an additional 291 shares during the last quarter. Wedmont Private Capital acquired a new stake in Halozyme Therapeutics during the 3rd quarter valued at approximately $294,000. Journey Retirement Planning & Investment Management LLC acquired a new stake in Halozyme Therapeutics during the 3rd quarter valued at approximately $332,000. Finally, Legacy Wealth Asset Management LLC increased its holdings in Halozyme Therapeutics by 38.5% during the 3rd quarter. Legacy Wealth Asset Management LLC now owns 5,210 shares of the biopharmaceutical company's stock worth $575,000 after purchasing an additional 1,447 shares during the last quarter. Hedge funds and other institutional investors own 97.79% of the company's stock.

Insider Buying and Selling

In related news, Director Matthew Posard sold 5,230 shares of Halozyme Therapeutics stock in a transaction dated Thursday, October 1st. The shares were sold at an average price of $108.54, for a total value of $567,664.20. Following the sale, the director directly owned 53,609 shares in the company, valued at $5,818,720.86. This trade represents a 8.89% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 20,000 shares of the business's stock in a transaction dated Thursday, October 8th. The shares were sold at an average price of $109.40, for a total transaction of $2,188,000.00. Following the transaction, the chief executive officer directly owned 767,780 shares of the company's stock, valued at $83,995,132. The trade was a 2.54% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 125,852 shares of company stock valued at $13,538,046 in the last quarter. Company insiders own 2.50% of the company's stock.

Halozyme Therapeutics Trading Down 1.3%

Shares of NASDAQ HALO opened at $109.62 on Wednesday. The company has a market cap of $12.44 billion, a price-to-earnings ratio of 32.72, a price-to-earnings-growth ratio of 0.42 and a beta of 0.88. Halozyme Therapeutics, Inc. has a 12-month low of $61.22 and a 12-month high of $116.85. The company has a current ratio of 2.71, a quick ratio of 2.31 and a debt-to-equity ratio of 13.50. The stock's 50 day simple moving average is $107.30 and its 200 day simple moving average is $83.87.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.79 by $0.49. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%. The company had revenue of $481.00 million for the quarter, compared to analysts' expectations of $402.28 million. During the same period last year, the business posted $1.54 earnings per share. The firm's quarterly revenue was up 47.7% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. Equities research analysts expect that Halozyme Therapeutics, Inc. will post 8.25 EPS for the current year.

Analyst Ratings Changes

Several equities analysts have recently commented on the company. JPMorgan Chase & Co. increased their target price on Halozyme Therapeutics from $70.00 to $78.00 and gave the company a "neutral" rating in a research note on Thursday, October 8th. HC Wainwright lifted their price target on shares of Halozyme Therapeutics from $115.00 to $130.00 and gave the stock a "buy" rating in a research note on Wednesday, October 7th. Weiss Ratings upgraded shares of Halozyme Therapeutics from a "buy (b-)" rating to a "buy (b)" rating in a research note on Monday, August 31st. Leerink Partners raised shares of Halozyme Therapeutics from a "market perform" rating to an "outperform" rating and upped their price target for the company from $83.00 to $110.00 in a report on Friday, August 7th. Finally, Wall Street Zen upgraded shares of Halozyme Therapeutics from a "buy" rating to a "strong-buy" rating in a research note on Saturday, August 8th. Nine research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $96.50.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that improve the administration of injectable medicines. The company's primary platform, ENHANZE, uses recombinant human hyaluronidase to temporarily modify tissue beneath the skin, allowing certain drugs and biologics that are traditionally delivered by intravenous infusion to be administered by subcutaneous injection.

Halozyme licenses its technology to pharmaceutical and biotechnology companies, which incorporate it into their own therapies.

Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.